Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550539 | 0.89 | FAAH (0.66) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL15602675 | 0.89 | FAAH (0.66) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL15623807 | 0.87 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL30838577 | 0.87 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL9526869 | 0.87 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL23376623 | 0.87 | ALDH1A1 (0.51) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL15435835 | 0.87 | ALDH1A1 (0.51) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL30838579 | 0.87 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL18674704 | 0.87 | ALDH1A1 (0.51) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL30838580 | 0.87 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023205237-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205233-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205241-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205245-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | FAAH 431/4885SMN1; SMN2 700/4885SLC6A5 1190/4885 |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | FAAH 431/4885SMN1; SMN2 700/4885SLC6A5 1190/4885 |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | FAAH 496/4885SMN1; SMN2 1038/4885SLC6A5 1183/4885 |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | FAAH 431/4885SMN1; SMN2 700/4885SLC6A5 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.